Hungary does not stop trials of remdesivir, although drug is not effective according to WHO



[ad_1]

Most of the content in the portfolio is available for free, as is this article.

However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more

According to a World Health Organization study of 11,000 coronavirus patients, remdesivir does not reduce mortality or recovery time, but previous research has shown that critically ill patients can reduce recovery time by up to a third.

“It is not that simple. That is why we are not going to stop a clinical trial because the World Health Organization announces it,” chief physician John Slavik told ATV.

I think we are doing the right thing by waiting for clinical trials to end and it can be said to be effective or ineffective, and so far we have emphasized that this is not a panacea.

The chief physician told the news channel.

Slavik sees that such an investigation result is not judged by the WHO, but by independent experts. Furthermore, it does not matter to whom, when, in what dose the active substance is administered.

The remdesivir experiments developed by Richter in Hungary began at the centers of four medical universities, two national institutes, and St. John’s Hospital.

Trade RICHTER shares on the Portfolio Online Exchange! Favorable conditions, professional customer service. Start

Cover image: Getty Images



[ad_2]